Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1, Open-Label, Multicenter Study of INCB123667 as Monotherapy and in Combination With Anticancer Therapies in Participants With Selected Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INCB 123667 (Primary) ; Antineoplastics; Bevacizumab; Fulvestrant; Olaparib; Paclitaxel; Palbociclib; Ribociclib
  • Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal cancer; Gynaecological cancer; HER2 negative breast cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Solid tumours; Triple negative breast cancer; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Incyte Corporation

Most Recent Events

  • 28 Aug 2025 Planned End Date changed from 30 Jul 2026 to 31 Aug 2027.
  • 28 Aug 2025 Planned primary completion date changed from 29 Aug 2025 to 27 Jul 2027.
  • 23 Apr 2025 According to an Incyte media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, 2025, in Chicago.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top